Cellectis S.A. Stock Forecast
NASDAQ: CLLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CLLS analyst consensus
Consensus (5 analysts)
none
Avg. price target
$5.33+326.40%
- Strong buy 0
- Buy 2
- Hold 2
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 5 Wall Street analysts covering Cellectis S.A. (2026-10-08), 2 rate the stock a buy or strong buy, 2 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $5.33, with a high estimate of $10.00 and a low estimate of $1.30. The average target implies upside of 326.4% from the current price of $1.25.
The spread between the highest and lowest targets is 669.2%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for CLLS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 2 | 40% |
| Hold | 2 | 40% |
| Sell | 0 | 0% |
| Strong sell | 1 | 20% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $1.30 | +4.00% |
| Average target | $5.33 | +326.40% |
| High target | $10.00 | +700.00% |